| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131356A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131327A1 Prostaglandin conjugates for treating or preventing bone disease |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131310A1 Chrystals of 5- 6-(2-fluorobenzyl)oxy-2-naphthyl methyl]-2,4-thiazolidinedione |
| 09/12/2001 | EP1131302A1 Substituted 4-amino-2-aryl-cyclopenta d]pyrimidines, their production and use and pharmaceuticalreparations containing same |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131090A2 Method of using pon-1 to decrease atheroma formation |
| 09/12/2001 | EP1131089A1 Stable aqueous insulin preparations without phenol and cresol |
| 09/12/2001 | EP1131074A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal |
| 09/12/2001 | EP1131070A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 09/12/2001 | EP1131065A2 Utilisation of dialkylfumarates |
| 09/12/2001 | EP1131064A2 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 09/12/2001 | EP1131060A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 09/12/2001 | EP1130980A1 Beverage for increasing the body's capacity to break down alcohol |
| 09/12/2001 | EP1130979A1 Calcium fortified juice-based nutritional supplement |
| 09/12/2001 | EP1032424B1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 09/12/2001 | EP0991424B1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 09/12/2001 | EP0888317B1 Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma |
| 09/12/2001 | EP0832066B1 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| 09/12/2001 | EP0831864B1 Processed ginseng having enhanced pharmacological effect |
| 09/12/2001 | EP0820450B1 N-substituted azaheterocyclic carboxylic acids and alkylesters thereof |
| 09/12/2001 | EP0814788B1 Improving glucose tolerance |
| 09/12/2001 | EP0764177B1 Crosslinked polymer containing composition for removing bile salts from a patient |
| 09/12/2001 | CN1312807A Inhibitors of glycogen synthase kinase 3 |
| 09/12/2001 | CN1312805A Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 09/12/2001 | CN1312800A Therapeutic biaryl derivatives |
| 09/12/2001 | CN1312795A New 3-aryl propionic acid derivatives and analogs |
| 09/12/2001 | CN1312724A TNF-drvived peptides of use in treating oedema |
| 09/12/2001 | CN1312719A Pharmaceutical Composition |
| 09/12/2001 | CN1312718A Selective estrogen receptor modulator in combination with sex steriod precursors and the like |
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312714A Pharmaceutical composition containing lipase inhibitors and chitosan |
| 09/12/2001 | CN1312713A Pharmaceutical compositions containing lipase inhibitors |
| 09/12/2001 | CN1312372A Intocostrin regulation area and nucleotide series determination and method used thereof |
| 09/12/2001 | CN1312254A Novel nucleoside |
| 09/12/2001 | CN1312071A Linolic acid and linolenic acid capsule and its making process |
| 09/12/2001 | CN1312070A Application of cinnamic acid, cinnamate and their derivative in preparing medicine |
| 09/12/2001 | CN1070866C Superagonists and antagonists and superantagonists of H IL-6, and 3-D modelling method for their selection |
| 09/12/2001 | CN1070705C Antidiabetic agent |
| 09/12/2001 | CN1070698C Medicinal treatment |
| 09/11/2001 | US6288249 Carbocyclic alcohols |
| 09/11/2001 | US6288218 Detecting gene expression in sample; incubate nucleotide sequences and primers, allow hybridization and detect hybridization products |
| 09/11/2001 | US6288104 Administering seretonin uptake inhibitors to treat depression, psychological and psychiatric disorders with an anxiety component, alcohol and drug dependence, bulimia nervosa and obsessive-compulsive disorders |
| 09/11/2001 | US6288096 Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives |
| 09/11/2001 | US6288094 Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments |
| 09/11/2001 | US6288093 Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments |
| 09/11/2001 | US6288090 Pharmaceutical composition |
| 09/11/2001 | US6288087 An extract from eupatorium purpurem, cytochrome p450 inducing compound, sugar, a source of phosphate, and one or more carriers |
| 09/11/2001 | US6288084 Administering comounds such as 4-(4-chlorophenyl)-1-(4-(3-methoxyphenyl)-4-(3-pyridinyl)-3 -butenyl)piperidin-4-ol to treat diseases associated with aberrant leukocyte recruitment and/or activation |
| 09/11/2001 | US6288083 Chemokine receptor antagonists and methods of use therefor |
| 09/11/2001 | US6288066 Antidiabetic agents; oxidation, hydrolysis |
| 09/11/2001 | US6288029 Template assembled synthetic peptide effective to treat respiratory system disorders |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | US6287757 Amino acid-trehalose composition |
| 09/11/2001 | US6287609 Unfermented gel fraction from psyllium seed husks |
| 09/11/2001 | US6287607 Bone loss |
| 09/11/2001 | US6287594 Oral liquid compositions |
| 09/11/2001 | US6287586 Pharmaceutical compositions of vanadium biguanide complexes and their use |
| 09/11/2001 | US6287576 Biostimulating agent |
| 09/11/2001 | CA2057578C 1,4-disubstituted piperazines, process for their preparation and pharmaceutical compositions containing them |
| 09/11/2001 | CA2037099C Crystalline salt of 4-(di-n-propyl) amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz ¢cd! indole |
| 09/11/2001 | CA2018824C Use of kojic acid for treating pigmentation diseases |
| 09/07/2001 | WO2001064907A2 Lipid metabolism enzymes |
| 09/07/2001 | WO2001064899A2 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method |
| 09/07/2001 | WO2001064884A2 G12l, a gene associated with the thermal response |
| 09/07/2001 | WO2001064879A2 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | WO2001064742A1 Modified bdnf |
| 09/07/2001 | WO2001064692A1 Cardioprotective phosphonates and malonates |
| 09/07/2001 | WO2001064679A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 09/07/2001 | WO2001064669A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | WO2001064668A2 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 09/07/2001 | WO2001064661A1 Antioxidants |
| 09/07/2001 | WO2001064645A2 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | WO2001064634A1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
| 09/07/2001 | WO2001064633A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | WO2001064632A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | WO2001064344A2 Microfabricated devices for the storage and selective exposure of chemicals and devices |
| 09/07/2001 | WO2001064234A1 Casein derived peptides and uses thereof in therapy |
| 09/07/2001 | WO2001064220A1 Use of trimetazidine to inhibit acyl-coa acetyl transferase |
| 09/07/2001 | WO2001064057A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2000054763A3 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone |
| 09/07/2001 | WO2000050580B1 Composition, methods and reagents for the synthesis of a soluble form of human phex |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401550A1 Casein derived peptides and uses thereof in therapy |
| 09/07/2001 | CA2401453A1 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |
| 09/07/2001 | CA2400657A1 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2372185A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/06/2001 | WO2001064715A2 Memno peptides, a process for their preparation and their use |